Pfizer Japan and Eisai Pharmaceuticals are set to launch postherpetic neuralgia treatment Lyrica capsules (pregabalin) in Japan on 22 June 2010.

Lyrica was approved in Japan in April 2010 and has been included on the National Health Insurance drug price list.

The drug, developed by Pfizer, has been approved in more than 105 countries worldwide, and its efficacy and safety has been proven in a number of clinical trials.

Lyrica is also listed as a first-line drug in the treatment guidelines for neuropathic pain (including postherpetic neuralgia) in the US and Europe.